New cell therapy aims to tame stubborn autoimmune diseases

NCT ID NCT07095075

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This early-stage study tests an experimental cell therapy called LUCAR-DKS1 in 36 adults whose autoimmune diseases (like lupus or vasculitis) have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will monitor side effects and measure how long the therapy lasts in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jiangsu Province Hospital

    RECRUITING

    Nanjing, Jiangsu, 210029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

    Contact

  • The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

    RECRUITING

    Hefei, Anhui, 230036, China

    Contact

  • The First Affiliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, Zhejiang, 325015, China

    Contact

    Contact

  • The Third The People's Hospital of BengBu

    NOT_YET_RECRUITING

    Bengbu, Anhui, 233000, China

    Contact

Conditions

Explore the condition pages connected to this study.